Explore the complete list of our presses below (Page 4 of 27):
A new initiative by IFC and The Netherlands aims to strengthen Jordan's pharmaceutical sector, enhancing exports and attracting foreign investments.
FDA approves Moderna and Pfizer mRNA Covid-19 vaccines targeting Omicron KP.2, offering enhanced protection for ages 6 months and up.
Avery Dennison introduces AD Minidose U9XM, a high-memory UHF RFID tag for precise tracking and authentication of small pharmaceutical items.
EyePoint Pharmaceuticals faces new FDA scrutiny over Yutiq manufacturing at its Watertown facility, following a Form 483 and recent warning letter.
OKYO Pharma secures U.S. Patent No. 12,053,501 for OK-101, enhancing dry eye disease treatment and strengthening its IP portfolio.
Sanofi halts flu vaccine distribution in China due to reduced effectiveness concerns. The pause affects Vaxigrip and VaxigripTetra for the 2024-25 season.
Bharat Biotech Launches HILLCHOL Oral Cholera Vaccine to Bridge Global Supply Gap with 200M Dose Production Capacity.
Chinese medical device companies are expanding globally to tackle domestic competition and regulatory hurdles, driving growth.
AIIMS Delhi partners with Osaka University to set up a center in Jhajjar for medical device development under "Make in India.
Pharma Now partners with Indian Vaccine Leaders Conclave 2024, spotlighting vaccine advancements, collaboration, and top achievers.
Explore Cardinal Health's new 8,000-sq-ft Advanced Therapy Innovation Center, offering cutting-edge logistics for cell & gene therapies in Tennessee.
Pharma giants Alkem and Entod seek Delhi HC relief to deplete banned FDC drug stocks, challenging a new government ban on 156 such combinations.
New Mpox variant Clade 1b spreads rapidly from Africa to Europe and Asia, prompting a global health emergency and a $135M funding call by WHO.
GAO audit exposes FDA's challenges in tracking medical device safety, highlighting risks to patient health and well-being
UCSB secures $22M NSF grant to create ExFAB, the first U.S. biofoundry focused on harnessing extreme microbes for innovative biotech solutions.
NSF invests $75M in 5 biofoundries to advance biology, AI, and health, democratizing research access and supporting innovation across diverse fields.
Novartis' Leqvio (inclisiran) shows promise in a Phase III trial, significantly lowering LDL-C levels in ASCVD patients, paving the way for regulatory approval.
Natco Pharma files with the FDA for a generic version of Novartis' Tabrecta, seeking 180 days of exclusivity. Shares drop as Sensex rises.
New PFAS-free method from Amsterdam scientists adds trifluoromethyl groups to drugs, enhancing safety and sustainability.
FDA cites Global Calcium for major production and documentation issues following Tamil Nadu plant inspection.
Pfizer launches PfizerForAll, a direct-to-consumer platform for easier access to treatments like vaccines and migraine therapies.
Irrimax Corporation introduces new kits to extend the use of its IRRISEPT solution, focusing on infection reduction and improved care.
OxiWear's FDA-approved ear-worn pulse oximeter revolutionizes real-time SpO₂ monitoring, enhancing patient care.
AMRA Profiler 4 secures EU MDR certification, paving the way for advanced body composition analysis in Europe.
India's BioE3 policy aims to drive innovation and bio-manufacturing, targeting Rs 25 lakh crore growth by 2030 while promoting a cleaner, greener economy.
FDA clears Cosmo IMD’s GI Genius hardware with ColonPRO AI, enhancing polyp detection and improving colorectal cancer screenings during endoscopy.
Lilly is ramping up GLP-1 production with advanced tech and sustainable practices to meet rising demand and minimize environmental impact.
Torrent Pharma's Indrad facility receives USFDA EIR with VAI classification, ensuring operations and reinforcing its position in regulated markets.
Zydus Lifesciences receives FDA approval for Scopolamine Transdermal System. Production to begin at Matoda facility; product targets nausea and motion sickness.
Sanyou Biopharmaceuticals introduces a new monkeypox product line with 65 items, including antigens, antibodies, and cell lines for diagnostics and research.
WHO urges manufacturers to submit mpox diagnostic tests for emergency use listing as cases rise in Africa, especially in the DRC.
WHO Regional Committee for Africa sets a goal for 55% local production of medicines and vaccines by 2035 to tackle health crises.
Kiyatec’s 3D Predict Glioma test improves survival rates for high-grade glioma patients by predicting chemotherapy response.
DePuy Synthes debuts MatrixSternum chest fixation system, claiming superior strength and reduced procedure time in surgeries.
Tanvex BioPharma secures U.S. FDA approval for Nypozi, a Neupogen biosimilar, and advances its TX-05 BLA for HER2-positive cancer treatment.
Emerging studies suggest semaglutide may offer anti-aging benefits, including reduced mortality and improved metabolic health in overweight individuals with cardiovascular conditions.
Swiss pharma firms, like Novartis, use patent battles to block generics and keep drug prices high, affecting global access and costs.
NXP800 earns FDA Orphan Drug status for ARID1a-deficient ovarian cancers, boosting development and exclusivity.
Servier Korea launches Tibsovo, targeting IDH1 mutation in cholangiocarcinoma and AML, offering new hope for patients with rare cancers.
GSK Boostrix vaccine sales halted due to a packaging defect, affecting two batches with future expiration dates.
Zealand Pharma's DREAM trial reveals dapiglutide reduces weight by up to 4.3% in 12 weeks with good safety and tolerability.
Bayer AG’s Kerendia demonstrates a 16% risk reduction in heart failure complications, boosting growth prospects amid challenges in its pharma division.
FDA warns Eugia Pharma for manufacturing lapses and data issues at its Telangana plant. Corrective actions required.
Biocon Pharma receives USFDA approval for its generic Sacubitril/Valsartan Tablets to treat chronic heart failure.
Cosmo IMD's GI Genius™ boosts polyp detection by 8.3% over standard colonoscopy, as revealed in a new Lancet study, advancing colorectal cancer screening.
GT201, Grit Biotechnology's advanced TIL therapy, secures U.S. FDA IND approval. A breakthrough in solid tumor treatment, powered by proprietary platforms.
Dr. Krishna Ella of Bharat Biotech challenges multinational priorities and media coverage, urging balanced innovation.
Aspivix’s Carevix device receives MHRA approval, advancing gynecology with enhanced patient comfort and care standards in the UK.
FDA authorizes Novavax’s updated COVID-19 vaccine; CDC recommends for individuals 12+ with nationwide distribution soon.
BioPhorum expands with Brookwood Global acquisition, boosting training services in clinical research and life sciences.
Emcure gains court relief from FDC ban, sparking industry debate on the regulation and approval of drug combinations.
Abbott and Medtronic partner to create a diabetes management system, combining FreeStyle Libre CGM with advanced insulin delivery for optimal glucose control.
Johnson & Johnson's nipocalimab aims for FDA approval as a new treatment for generalized myasthenia gravis, showing promising Phase 3 results.
GSK's hepatitis B drug bepirovirsen earns FDA Fast Track status amid a series of promising treatment updates.
Aurobindo Pharma accelerates its specialty portfolio with 14 biosimilars, boosting supply chain efficiency and investing heavily in R&D and biologics.
Explore cutting-edge PNH treatments, including crovalimab and PiaSky, revolutionizing care with new therapies and improving patient outcomes.
The ARC Centre of Excellence in Quantum Biotechnology aims to revolutionize biotechnology and biosciences in Australia.
Entod Pharmaceuticals secures DCGI approval to market PresVu, India's first eye drops for presbyopia treatment
Sareum Holdings obtains US patent for SDC-1801, protecting its innovative autoimmune disease therapy.
Innocan Pharma secures FDA support for expedited approval of its LPT-CBD drug, advancing chronic pain treatment innovation.
Athira Pharma's LIFT-AD study showed fosgonimeton didn't meet primary endpoints but showed promising biomarker and subgroup results.
Zydus Lifesciences receives FDA warning for its Jarod plant after Form 483 citations; plans to address the issues promptly and ensure compliance.
Acepodia teams up with Pfizer Ignite to advance its Nobel-winning cell therapies for cancer and autoimmune diseases, without financial transactions.
Lilly and EVA Pharma partner to locally produce baricitinib, aiming to improve healthcare access in 49 African countries.
Essential Pharma acquires Renaissance Pharma, adding Hu14.18 to its portfolio to address pediatric oncology needs.
Roche's fenebrutinib reveals potential in MS treatment, with positive Phase II extension results presented at ECTRIMS.
Recipharm’s ReciPredict platform applies Quality by Design to accelerate drug development, cut API use by up to 70%, and ensure efficient tech transfers.
Olon plans to acquire HuvePharma Italia Srl and its Garessio facility, boosting production capacity. This expands Olon's presence in Italy and API expertise.
AdvaMed earns ANSI accreditation to set new standards for medical imaging, cybersecurity, and AI, driving innovation in medtech.
MHRA approves Moderna's updated Covid-19 vaccine targeting the JN.1 variant, available via NHS and private purchase for high-risk individuals.
Novartis invests $200M in U.S. radiotherapy with new facilities in California and upgrades in Indiana to boost production and tackle isotope shortages.
EMA's pilot program offers free expert guidance to advance orphan medical devices for rare and pediatric conditions.
The FDA has published a paper on health equity in medical devices, requesting public feedback on key considerations.
Abbott teams up with Beta Bionics to integrate FreeStyle Libre with iLet Bionic Pancreas, streamlining diabetes care.
Paragonix partners with NORA to create a new organ transport service using commercial flights to improve distribution equity.
Astellas opens a new life sciences hub in Massachusetts, featuring a cutting-edge SakuLab to foster biotech innovation and collaboration with 400 employees.
CHECK and RWEAL studies reveal high prevalence of chronic hand eczema in Europe and Canada, stressing the need for better treatments.
Purdue Pharma wins an 18-day extension to continue settlement talks over the Sacklers' role in the opioid crisis, amid criticism and legal scrutiny.
Emcure launches Arth, a range of products focused on easing menopause symptoms and empowering women's health.
Evotec partners with X-Chem to accelerate early drug discovery using DEL technology and advanced data mining tools.
WHO launches guidance to curb antimicrobial resistance by addressing antibiotic pollution from manufacturing waste.
Takeda partners with Sun Pharma and Cipla to commercialize Vonoprazan in India, targeting GERD treatment needs.
Lotus Pharmaceutical acquires Alpha Choay rights from Sanofi in Vietnam & Cambodia, enhancing its anti-inflammatory drug market presence in Southeast Asia.
BlueRock’s OpCT-001 gets FDA IND approval for treating primary photoreceptor diseases. Phase 1/2a trial launching soon.
Novartis CEO Vas Narasimhan announces a $1 billion deal to sell U.S. dermatology and generics divisions to India's Aurobindo Pharma, driving strategic refocus.
NImmune teams up with BioTherapeutics to enhance immunology therapeutics with preclinical and regulatory expertise.
Qiagen and Eli Lilly team up to create an in vitro diagnostic for Alzheimer's detection using APOE genotyping.
Ivonescimab shows significant promise in treating NSCLC, reducing disease progression by 49% over Keytruda.
Firebrick Pharma's Nasodine nasal spray is under review in Europe, with approval anticipated by December 2024.
Sun Pharma and Moebius Medical receive USFDA fast track designation for MM-II, a non-opioid knee osteoarthritis therapy.
Nano4Imaging teams with Arrotek to enhance U.S. production and development of MRI-compatible medical devices.
Suven Pharmaceuticals' share price jumped 3.67% to Rs 1,245 after its Hyderabad facility received a VAI status from the US FDA.
AstraZeneca's new inhalers with a 99.9% eco-friendly propellant mark a major step in cutting greenhouse gas emissions.
Cizzle Biotech partners with Moffitt Cancer Center to test its CIZ1B biomarker for early lung cancer detection.
ProKidney announces strategic updates for rilparencel Phase III trials, targeting faster FDA approval process.
Agilent Technologies launches its Biopharma CDx Services Lab, offering cutting-edge diagnostics and precision medicine solutions for biopharma clinical trials.
Scantox Group acquires UK-based Gentronix, a leader in genetic toxicology, expanding services and global reach in predictive toxicology for drug development.
Newcells Biotech's CiliaBeat software and Lung Ciliary Beat Frequency Assay revolutionize drug testing with precise, predictive insights on ciliary function.
Aptar Pharma partners with PULMOTREE to advance the Kolibri™ Non-Propellant Inhaler, enhancing drug delivery with comprehensive support.
Formosa Pharmaceuticals has shipped its new clobetasol ophthalmic suspension to the US, marking a major step towards its September 2024 launch.
India to locally manufacture Clavulanic Acid and Penicillin G under the PLI scheme, boosting antibiotic production.
GST Council reduces tax on cancer drugs to 5%, enhancing affordability and accessibility for patients across India.
FDA clears Femasys' FemCheck, a diagnostic tool for fallopian tube occlusion, supporting non-surgical birth control.
Abbott rolls out Aveir DR leadless pacemaker in the UK, a dual-chamber system that improves heart rhythm treatment.
Keen Vision Acquisition Corp. and Medera to merge, creating a $622.6M entity focused on gene therapies and Nasdaq listing.
CPHI Milan announces 2024 Pharma Awards finalists, featuring new "Woman of the Year" and "Future Leader" categories celebrating industry innovation.
Roche opens its state-of-the-art pRED Center in Basel, enhancing global R&D collaboration to accelerate innovation and improve patient outcomes.
Novartis is expanding with a new California facility and an Indianapolis upgrade to boost radiopharmaceutical production and meet growing demand.
iCardio.ai partners with SARC MedIQ to integrate AI into ultrasound imaging, improving diagnosis speed and accuracy.
Vasa Therapeutics' lead drug, VS-041, enters clinical trials, aiming to treat heart failure with preserved ejection fraction.
Pharma Now announces media partnership with Pharma Packaging and Labeling Forum 2024, covering innovations and trends.
Nxera Pharma Co. recognizes Centessa's promising Phase 1 results for ORX750, a potential narcolepsy treatment, demonstrating strong safety and efficacy.
Ascendis Pharma's YORVIPATH secures FDA Orphan Drug exclusivity for treating adult hypoparathyroidism, granting seven years of U.S. market exclusivity.
Chicago Rockford International Airport (RFD) launches a GDP-certified pharma trade lane from India, boosting efficiency and cutting CO2 emissions.
BIOCAPTIVA’s new US patent for liquid biopsy tech boosts cfDNA extraction, enhancing disease detection and personalized medicine.
Sanofi and Regeneron's Dupixent shows strong potential in treating bullous pemphigoid, chronic urticaria, and COPD, possibly changing treatment standards.
GSK’s HSV vaccine candidate fails phase II, halting progress. The company continues safety and follow-up analysis.
Novo Nordisk's weight loss pill shows promising early results, with up to 13% body weight loss in 12 weeks.
BGS Beta-Gamma-Service opens its first U.S. sterilization facility, addressing growing demand for E-Beam technology.
Turbine’s AI platform helps Ono identify cancer targets, accelerating drug discovery with in vitro validation.
Tesla BioHealing and Cell Biotechnology partner to revolutionize stem cell therapies with advanced biophoton technology.
Sino Biological and BioGeometry team up to revolutionize protein design and optimization with advanced AI technology.
Pharma M&As drive innovation, expand reach, enhance healthcare solutions, and strengthen market positions worldwide.
DeCODe consortium launches to support paediatric and orphan device development for children with rare diseases in Europe.
C2 PHARMA introduces Naphazoline HCL, a versatile API for red eyes and nasal relief. Awaiting CEP approval, with US-DMF and Brazil filings set for 2024.
Zeto teams up with Firefly Neuroscience to integrate AI with EEG headsets, improving brain health diagnostics.
Nona Biosciences and Umoja Biopharma partner to develop novel CAR-T cell therapies using proprietary antibody platforms.
NS Pharma's NS-050/NCNP-03 for Duchenne receives FDA Rare Pediatric Disease status, bringing new hope with its exon-skipping approach.
Arrowhead Pharmaceuticals’ RNAi treatment, plozasiran, gains FDA breakthrough status, speeding up development for rare genetic condition FCS.
Moderna’s mRNA-4359 vaccine shows promise in early trials for advanced cancer, boosting immune response with minimal side effects.
AdjuTec Pharma begins Phase I trials for APC148, targeting antibiotic resistance, with safety studies starting on Sept 18 in Uppsala, Sweden.
FDA authorises first over-the-counter hearing aid software for AirPods Pro, making hearing support more accessible.
Biocomposites introduces its NanoBone product range in the UK, providing surgeons with cutting-edge bone graft solutions.
Merck's KEYTRUDA improves 5-year overall survival by 34% in high-risk early-stage TNBC, showing a significant benefit.
MOB-015 Phase 3 trial shows fewer clinical cures than expected; Cypher holds Canadian commercialization rights.
Prelude's PRT3789 shows early efficacy in Phase 1 trial, reducing tumors in SMARCA4-mutated cancers with mild to severe effects.
Ascendis Pharma's TransCon IL-2 β/γ shows 29% clinical response in pretreated, platinum-resistant ovarian cancer patients.
Richter Biologics unveils its new P2 production facility, expanding capacity for pDNA, vaccines, nanobodies, and recombinant proteins, with a €95M investment.
Aarti Drugs and IPCA Laboratories face ransomware attacks; sensitive financial and employee data exposed online.
Eli Lilly's eczema drug, Ebglyss, gets FDA approval for adults and children over 12, offering monthly doses for atopic dermatitis. Available soon in the US.
FDA approves Strides Pharma's generic fluoxetine, boosting dosage options and expanding the market for depression treatment.
Piramal Pharma's GHG reduction goals get SBTi approval, aiming for a 42% cut in scope 1 and 2 emissions by FY2030.
J&J MedTech’s Shockwave Medical introduces the E⁸ IVL catheter, tackling complex peripheral artery disease
FDA approves Roche’s Ocrevus Zunovo, the first subcutaneous injection for relapsing and primary progressive MS.
Myeloid Therapeutics debuts Aurora Biosynthetics in Sydney to drive GMP production of RNA therapeutics in Asia-Pacific.
APIIC secures $16.4M to produce crucial APIs for asthma, diabetes, and anxiety, boosting U.S. pharmaceutical manufacturing and supply chain resilience.
Argon Medical launches a Thrombectomy system CLEANER Vac™, that aids blood clot removal, eases technically compound procedures for physicians.
Tonix Pharma's TNX-801 mpox vaccine meets WHO criteria, promising single-dose effectiveness and ambient temperature stability.
Utah will resume its lawsuit against Richard Sackler and Purdue Pharma, seeking justice for deceptive OxyContin marketing after a 60-day pause.
Smith’s Medical Recall Airway tubes, linked to several injuries & one death, received warning letters and frequent quality problems.
Epitomee Medical gains U.S. FDA clearance for its drug-free Epitomee® Capsule, helping adults with BMI 25-40 manage weight through diet and exercise.
Sanofi ships BEYFORTUS, the first RSV prevention antibody for infants, to healthcare providers ahead of RSV season.
Zentalis announces FDA has lifted the hold on azenosertib studies. The company will reveal new data and updates at a corporate event later this year.
nfigratinib by BridgeBio earns FDA Breakthrough Therapy Designation, advancing treatment options for achondroplasia.
Boston Scientific’s INGEVITY™+ Pacing Leads now FDA-approved for expanded use in conduction system pacing and left bundle branch area monitoring.
Liquidia secures a win as United Therapeutics is found liable for $137M in losses over delayed Treprostinil launch.
Capricor Therapeutics and Nippon Shinyaku bind a term sheet for augmentation of sales and development of Deramiocel.
LEO Pharma launches a single-dose auto-injector for Adbry (Tralokinumab) in the U.S., enhancing treatment for moderate-to-severe atopic dermatitis.
Novo Nordisk GBS launches Eco Med Safe to revolutionize medication disposal and safeguard the environment.
GSK partners with Brooke Shields for THRIVE@50+, empowering those over 50 to prioritize health, raise shingles awareness, and embrace aging confidently.
The MHRA launches a strategy to transform safety communications, providing clear, targeted safety updates for the UK.
MIRA Pharmaceuticals aims to demonstrate clinical efficacy of its oral ketamine analog in 2025 with Phase I/II trials.
AstraZeneca’s Fasenra approved by FDA for EGPA, a rare vasculitis. It helps patients reduce dependence on steroids.
Aligos Therapeutics to announce Phase 2a results for MASH treatment ALG-055009 and host webcast on September 19, 2024.
Rocket Pharmaceuticals completes enrollment for pivotal Phase 2 trial of RP-A501, a gene therapy for Danon disease.
Merck’s KEYTRUDA gains FDA approval for first-line use in advanced mesothelioma, improving survival when combined with chemotherapy.
Plus Therapeutics will present its innovative radiotherapeutics for GBM and CNS cancers at the 2024 CNS Annual Meeting in Houston, TX.
BioMarin's ISDS 2024 data shows VOXZOGO® boosts height and quality of life in children with achondroplasia and other genetic disorders.
Pharma Now partners with Evolution Summit 2024 to spotlight clinical trial innovations and insights.
Zydus Lifesciences recently announced its acquisition of Sterling Biotech’s API for cash compensation of Rs 84 crore.
Charles River and CEBINA announce collaboration for novel neuroscience research, fulfilling medical needs globally.
Patients with EGFR-mutated NSCLC who had previously received EGFR-TKI treatment were treated with Patritumab Deruxtecan and achieved vital endpoints.
Genentech's Xofluza reduces influenza transmission in a Phase III trial, showing promise for pandemic preparedness.
Newron Pharmaceuticals reports strong clinical progress with evenamide for schizophrenia, plus H1 2024 financial updates.
Hyphens Pharma launches Ceradan® Advanced Hand Balm with patented pH control, offering targeted relief and protection for hand eczema.
Pharma Now to cover key trends and innovations at the Global Pharma Supply Chain & Logistics Forum, Munich 2024.
GSK's Blenrep, in combination therapies, is under review by Japan's MHLW for relapsed/refractory multiple myeloma.
Astellas Pharma’s DIGITIVA™ earns FDA listing as a Class I SaMD, debuting in the U.S. digital health market with at-home heart failure monitoring.
Takeda to disclose new data on TAK-861 for Narcolepsy at Sleep Europe 2024, September 24-27 in Seville, Spain”
Tonix Pharmaceuticals gets U.S. Patent No. 12,090,139 for Tosymra®'s intranasal migraine treatment, enhancing its market position and IP protection.
Hovione and iBET launch ViSync® in Portugal to enhance drug delivery and stabilization in cell and gene therapy, combining expertise in pharma and biotech.
Abbott India signs an agreement with Takeda to commercialize Vonoprazan, offering better GERD treatment options.
Novartis reports significant Kesimpta outcomes in reducing MS progression, showing promise for first-line treatment.
FUJIFILM Irvine Scientific's Oceo Rover, automated hydration system changing media prep and bioprocessing efficiency.
Achilles Therapeutics halts its TIL-based trials, shifts focus to new cancer treatments, and explores strategic options with BofA Securities.
Glenmark Pharmaceuticals' Aurangabad plant successfully passes U.S. FDA inspection with zero observations.
FDA approves Sarclisa with VRd for newly diagnosed multiple myeloma patients, improving progression-free survival by 40%.
Lupin receives FDA approval for generic Bumetanide Injection, used to treat edema linked to heart, liver, and kidney diseases.
AbbVie’s ELAHERE® receives EMA recommendation for treating platinum-resistant ovarian cancer after prior therapies.
EMA recommends Pfizer-BioNTech's Omicron KP.2-adapted COVID-19 vaccine for individuals 6 months and older in the EU.
Teva's SOLARIS trial shows TEV-749, a monthly injectable, reduces schizophrenia symptoms with no PDSS and a strong safety profile.
Dupixent receives a positive opinion from European regulators for treating eosinophilic esophagitis in young children.
Zeposia shows sustained brain volume loss reduction and maintains safety in long-term study for multiple sclerosis.
Teva presents new data on transitioning schizophrenia patients from Perseris® to UZEDY® at ECNP Congress.
Imexpharm focuses on talent recruitment, R&D, and global expansion to secure a leading position in Vietnam’s pharmaceutical market.
AdjuTec Pharma launches phase 1 trial for APC148, aiming to combat antibiotic resistance and improve public health.
Longboard’s lead candidate, bexicaserin, gains FDA Rare Pediatric Disease and Orphan Drug designations for Dravet syndrome.
HudsonAlpha team employs long-read sequencing to re-analyze genomes, improving diagnostic rates for rare genetic disorders.
Huawei establishes an AI driven system that aids accuracy, diagnosis and intelligent quality control.
Pharma Giant Novo Nordisk to reveal the massive demand for its weight loss drugs, Ozempic and Wegovy.